Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

and health insurers who include Repatha on their formularies, but the high list price inflated co-payment costs to patients. Now, Amgen is hoping that reducing the co-pay will lead to an ...

Amgen’s PCSK9 drug Repatha costs $14,000 per year, and insurers often don’t cover it; in fact, a new study looking at 44,000 prescriptions for PCSK9 drugs showed that only 17 percent were covered.

The choice between Repatha and Leqvio often boils down to individual patient needs, preferences, cost, and insurance coverage. Ultimately, the decision should be made in collaboration with your ...

The Business Research Company's Repatha Global market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase ...